All In Biotech

Drug Trial Radar · NCT06389292

A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia

A Global, Multicenter, Randomized, Double-blind, Phase 3 Pivotal Registrational Clinical Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (GLORA-3)

Last checked: Nov 19, 2026Latest source record: Nov 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Title says "pivotal". Randomized with 486 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

486

Planned (sponsor's estimate)

Start

Jun 11, 2024

Primary completion

May 25, 2028

Study completion Mar 26, 2029

Sponsor

Lead sponsor
Ascentage Pharma Group Inc.Industry
Sponsor type
Industry
First posted
Apr 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A global, multicenter, randomized, double-blind, placebo-controlled, phase III pivotal registration study, to evaluate the efficacy of APG-2575 (Lisaftoclax) combined with azacitidine (AZA) versus placebo combined with azacitidine in newly diagnosed acute myeloid leukemia who are not eligible for standard induction chemotherapy.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • APG-2575(Lisaftoclax )Drug

    QD, oral administration, every 28 days for a dosing cycle.

  • PlaceboOther

    QD, oral administration, every 28 days for a dosing cycle.

  • Azacitidine InjectionDrug

    QD, subcutaneous or intravenous injection, D1-7 in 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival(OS)Time frame: Up to 5 years

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Hematology Hospital of the Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China · Recruiting

  • The First Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

  • Moscow Multidisciplinary Clinical Center "Kommunarka"

    Moscow, Russia · Recruiting

  • Botkin Moscow Multidisciplinary Research and Clinical Center

    Moscow, Russia · Recruiting

  • Russian Research Institute of Hematology and Transfusiology of the Federal Medical and Biological Agency

    Saint Petersburg, Russia · Recruiting

  • Leningrad Regional Clinical Hospital

    Saint Petersburg, Russia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.